Abstract: Antiperspirant active composition of enhanced efficacy containing a zinc salt and an efficacy enhancing agent selected from the group consisting of amino acid, hydroxy acid and a mixture thereof is disclosed. Specifically, a shelf-stable antiperspirant active solution containing an aluminum or aluminum-zirconium salt, a zinc salt, and the efficacy enhancing agent, which maintains the peak 4 concentration of at least 10% upon aging is disclosed. The present invention also includes methods of making the antiperspirant active solutions and formulations containing same.

Abstract: The present invention is directed to a rinse-off cleansing composition comprising from about 0.1 wt. % to about 12 wt. % of a 1,2-diol having a carbon chain with a length of more than 8 carbons; from about 0.1 wt. % to about 10 wt. % of a solid particle, wherein (1) the interfacial tension between the solid particle and sebum is from about 5 to about 18 dyn/cm; (2) the sebum exhibits spreading coefficient on the solid, which is greater than about 22 dyn/cm; and (3) the work of adhesion of the sebum to the solid particle, which is greater than about 75 dyn/cm. and an aqueous carrier.

Abstract: The invention relates generally to liquids such as mouth rinses for the prevention and elimination of bad breath as well as for the reduction of oral microorganisms responsible for the development of dental plaque and tooth decay. In particular, the present invention relates to a method of preparing non-alcohol or reduced alcohol mouth rinses effective at preventing the above-mentioned problems.

Abstract: The present disclosure relates to an anti-dandruff cleansing composition comprising: (a) salicylic acid; (b) a surfactant system comprising: (i) one or more non-sulfate anionic surfactants; (ii) one or more amphoteric surfactants; (iii) at least 10 wt. % of a plurality of nonionic surfactants comprising: (iii-a) one or more alkyl polyglucosides; and (iii-b) one or more amide surfactants; and (c) water; wherein all weight percentages are based on the total weight of the cleansing composition. The anti-dandruff cleansing compositions effectively treat dandruff and provide good cleansing and other desirable performance properties. Therefore, the compositions are particularly useful in methods for treating dandruff, for cleansing hair, and for providing a variety of other cosmetic benefits to the hair.

Abstract: A transparent cosmetic composition that provides an excellent feeling in use and excellent dissolution stability of ceramide is provided. The cosmetic composition of the present invention comprises (a) a ceramide, (b) a surfactant, and (c) water, wherein the cosmetic composition comprises (a) in an amount of 0.00001 to 5.0% by weight based on the total weight of the cosmetic composition, a polyglycerin aliphatic ether as (b) in an amount of 0.1 to 5.0% by weight based on the total weight of the cosmetic composition, and (c) in an amount of 50.0% by weight or more based on the total weight of the cosmetic composition. It is preferable that the polyglycerin aliphatic ether comprise a polyglycerin monoaliphatic ether in an amount of 75% by weight or more based on the total weight of the polyglycerin aliphatic ether and a polyglycerin dialiphatic ether in an amount of 5% by weight or less based on the total weight of the polyglycerin aliphatic ether.

Abstract: An oral care composition comprising (i) basic amino acid in free or salt form, (ii) calcium carbonate, (iii) a fluoride ion source, (iv) a flavoring agent comprising less than 50% menthol, and (v) an anionic surfactant, wherein the anionic surfactant is present in an amount from 1.00 weight % to 1.39 weight % is provided.

Abstract: The present disclosure relates to a concentrated rinse-off cleansing composition that includes a high concentration of surfactants and conditioning agent(s). For example, the cleansing compositions may include: (a) surfactants system comprising: (i) one or more anionic surfactants selected from: (i-a) alkyl sulfates, alkyl ether sulfates, salts thereof, or a mixture thereof; and (i-b) optionally, one or more non-sulfate anionic surfactants; (ii) one or more alkyl polyglucosides; and (iii) one or more amphoteric surfactants; (b) one or more conditioning agents; and (c) water. The cleansing compositions are particularly useful for cleansing hair.

Abstract: The present disclosure relates to a concentrated rinse-off cleansing composition that includes a high concentration of surfactants and conditioning agent(s). The cleansing compositions include: (a) a surfactant system comprising: (i) one or more non-sulfate anionic surfactants; (ii) one or more alkyl polyglucosides; and (iii) one or more amphoteric surfactants; (b) one or more conditioning agents; and (c) water. The cleansing compositions are particularly useful for cleansing hair.

Abstract: An aqueous surfactant composition containing one or more alpha-sulfo fatty acid disalt (A) of general formula (I), R1CH(SO3M1)COOM2??(I), in which the radical R1 is a linear or branched alkyl or alkenyl radical having 6 to 18 carbon atoms and the radicals M1 and M2, independently of one another, are selected from the group comprising H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine, one or more protein derivative (B2), wherein the protein derivatives (B2) are reaction products of one or more protein hydrolyzates (B1) with a substance selected from fatty acids, fatty acid chlorides, cationization reagents, and protein hydrolyzates (B1), wherein the protein hydrolyzates (B1) are proteins, peptides, and/or amino acids produced by chemical and/or enzymatic hydrolysis of proteins from plant or animal sources, and water.

Abstract: The present disclosure relates to color base compositions, as well as methods and kits using same. Certain compositions comprise: (a) about 0.05 to about 10 wt. % of at least one 3-aminopyrazolo[1,5-a]pyridine; (b) from about 0.01 to about 1 wt. % of a reducing agent other than thiolactic acid; (c) from about 0.01 to about 5 wt. % of an ammonia compound; (d) from about 5 to about 10 wt. % of an alkanolamine; (e) from about 0.01 to about 6 wt. % of a carboxylic acid-containing surfactant; and (f) from about 0.01 to about 1 wt. % of an antioxidant.

Abstract: Disclosed are triazine compounds of formula (I): wherein R is as defined in the description, as light stabilisers and photoprotectors against UV-visible radiation.

Abstract: The present disclosure describes a topical composition, and related masks comprising the compositions disclosed herein, for applying to skin for treating acne or skin rejuvenation, the compositions comprising a light activated enzymatic extract; adaptogenic Baobab (Adansonia digitata) seed extract; adaptogenic wild indigo (Tephrosia purpurea) extract; pre- and/or pro-biotic extracts; and a carrier. The mask may be embodied in, or comprise, a hydrogel matrix or a biocellulose material or other fibrous material.

Abstract: The present invention relates to a composition in the form of a nano- or micro-emulsion, comprising: (a) at least one oil; (b) at least one nonionic surfactant with an HLB value of from 8.0 to 14.0, preferably from 9.0 to 13.5, and more preferably from 10.0 to 13.0; (c) at least one ceramide compound; (d) at least one compound selected from Vitamin B3 and derivatives thereof; and (e) water. The composition according to the present invention can be used as a cosmetic composition and can enhance or improve the penetration of a ceramide compound into a keratin substance such as the skin.

Abstract: The present invention relates generally to methods of use and compositions useful for reducing the appearance of fine lines and wrinkles, moisturizing skin, promoting hydration, strengthening and repairing skin, reducing inflammation and redness, reducing oxidizing agents, protecting against pollution, reducing skin desquamation, reducing skin roughness, increasing skin lubricity, improving skin barrier function, and firming and conditioning skin. The composition includes a combination of one or more of saccharide isomerate, sodium carrageenan, sea salt, and sodium hyaluronate.

Abstract: Compositions and methods include an antibacterial particle comprising a cationically charged polymer and a salt.

Abstract: The invention presents a fast-drying nail enamel composition with good stability, easy application, high shine and long wear. The disclosed combination of an acrylic resin having a Tg greater than a threshold temperature; a second resin having a Tg less than the threshold temperature; at least one plasticizer selected from the group consisting of a benzoic acid derivative, a citric acid derivative, and an isobutyrate derivative; a non-polar silicone copolymer; and at least one solvent having an evaporation rate greater than butyl acetate provides a nail polish that can be dried within 40-60 seconds on fingernails without sacrificing other critical properties such as shine and wear resistance.

Abstract: A silicone resin represented by formula (1) and having a Mw of 1,000-8,000 is useful in cosmetics. [(C6H5)3SiO1/2]a[R13SiO1/2]b[R22SiO2/2]c[R3SiO3/2]d[SiO4/2]e??(1) R1 is a C1-C8 alkyl group, C6-C12 aryl group (exclusive of phenyl) or C1-C8 fluorinated alkyl group, R2 and R3 are each independently a C1-C8 alkyl group, C6-C12 aryl group or C1-C8 fluorinated alkyl group, a=0-0.2, b=0.1-0.5, c=0-0.2, d=0.01-0.5, e=0-0.6, a+b+c+d+e=1.0, at least one phenyl group is included in the molecule. A film of the silicone resin has a refractive index of at least 1.48.

Abstract: A method of treating the hair including providing a concentrated hair care composition in an aerosol foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the aerosol foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the aerosol foam dispenser.

Abstract: A compound for the cleansing of human underarm skin includes a natural cleansing agent, a natural antibacterial agent, a natural abrasive agent, a natural bulking agent, a natural preservative, a natural thinning agent, a natural antioxidant agent, a natural anti-mold agent, and a natural anti-viral agent.

Abstract: Facial hydrating oil compositions comprise sweet almond seed oil, carrot seed oil, rose hip seed oil, and a tocopherol. Such compositions are useful as cosmetics for hydrating skin and minimizing formation of fine lines and wrinkles.

Abstract: The sole purpose of this cosmetic invention was to make deodorant that is safe to use without aluminum that effectively prevents bad odor. The formulation used has been a challenge. I worked on the computations of this deodorant, it truly works and allows you to naturally sweat so not to occlude the pores and at the same time prevents malodor. This natural deodorant is safe, effective and free from any harmful chemicals.

Abstract: A cytomimetic formulation is provided comprising at least two of: (a) a fermented truffle extract; (b) a plurality of hyaluronic acids of different molecular weight, ranging from 50 KDa up to 2000 KDa; (c) an olive leaf extract in a mineral-containing water; and (d) a fermented grape must. The formulations mimic the skin cytoplasmic environment and create optimal conditions for cellular growth and skin rejuvenation. Methods of use and processes for manufacturing thereof are also provided.

Abstract: The present specification relates to a method for extracting a plant by using a skin serum that can be used for skin care. This method can further increase the process efficiency and extract active ingredients more effectively than conventional extraction methods using a solvent. Thus, the method can increase customer satisfaction and promote the development of relevant industries.

Abstract: Provided are: a method for producing an oral composition suitable for treatment or prevention of a disease or symptom in the oral cavity; and an oral composition produced by the production method. The oral composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the oral composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Abstract: Lactobacilus reuteri CH53 strain has high productivity of 1,3-propanediol from glycerol and uses thereof. It is confirmed that Lactobacilus reuteri CH53 strain is capable of converting at very high yield glycerol or crude glycerol to high-concentration 1,3-propanediol. Since Lactobacilus reuteri CH53 strain of the present invention capable of producing large amounts of 1,3-propanediol is one kind of lactic acid bacteria that are safe for humans (GRAS, Generally Recognized As Safe), when it is used for producing 1,3-propanediol from crude glycerol, it would be very advantageously used, unlike existing GMO strains, in related industries from the viewpoint of safety or environment and also providing an advantage of recycled use of resources.

Abstract: The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.

Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.

Abstract: A drug delivery system configured to be inserted transvaginally. The drug delivery system includes an outer skin defining a reservoir, and a mixture of a carrier oil and one or more cannabinoids inside the reservoir. The outer skin of the drug delivery device is permeable to the mixture of the carrier oil and the one or more cannabinoids. The drug delivery device may be a resilient ring, and the one or more cannabinoids may include Cannabidiol and less than approximately 0.03% Tetrahydrocannabinol.

Abstract: Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the article includes dimensions configured for transesophageal retrieval. In some cases, the articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.

Abstract: The present invention relates to a process of producing a nano-CBD microemulsion system includes: (i) preparing a dispersal phase by dissolving CBD in an ethanol solvent in a ratio between mass of CBD:volumn of ethanol solvent as 8:10 at a speed of 300 to 500 rpm with heating to a temperature ranging from 40 to 60° C. within 4 to 8 hours; (ii) preparing a carrier by heating a liquid PEG (polyethylene glycol) accounted for 40-60% by mass of the mixture of PEG and water to a temperature from 60 to 80° C., stirring homogeneously; (iii) adding the carrier to the dispersal phase in a ratio by mass of 40:60, continuing heating the dispersal phase to a temperature of 40 to 60° C., stirring at a speed of 400 to 800 rpm; (iv) elmusifying as follows: when the temperature arrives at 100° C., adding ACRYSOL K-140 to the mixture of the carrier and dispersal phase obtained in step (iii) in a ratio by mass of 40:60, continuing to stir at a speed of 500 to 700 rpm, at a temperature of about 100° C.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

Abstract: Disclosed are compositions comprising a first liposome, comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and at least one vasodilator; and a second liposome, comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, at least one thiazolidinedione, and at least one compound having an affinity for at least one component of an atheroma. Also disclosed are methods for forming the compositions and methods of using the compositions to ameliorate atheroma.

Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.

Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles.

Abstract: Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation f) products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments.

Abstract: The present invention relates to a recombinant exosome containing hyaluronidase and a use thereof, and more particularly to a recombinant exosome that presents hyaluronidase on its surface and use thereof as an anticancer agent.

Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channelguides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.

Abstract: The present disclosure relates to a taste-masking microcapsule composition. The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API.

Abstract: The present invention provides compositions comprising biodegradable particles that encapsulate two or more epitopes linked together by one or more linkers that are susceptible to cleavage by specific proteases. The present invention further provides methods for inducing antigen-specific tolerance and protective immune responses and for the treatment inflammatory diseases, such as autoimmune diseases, allergies, cancers, or infectious diseases.

Abstract: The disclosed bead vectors direct entry into a cell of monocytic origin and cause the expression of an extracellular domain of PD-1, an anti-CTLA4 antibody, or an antibody that is specific for a checkpoint protein. The bead vectors can comprise a nucleic acid component, a lysosome evading component and a bead particle that can be phagocytized. The disclosed vectors are useful in various methods of cancer therapy, treatment, and prevention. Due to the ability of monocytic cells to target tumors, the disclosed vectors are particularly well suited for use in anti-tumor applications and directing expression of target genes in tumor-associated macrophages.

Abstract: Compositions are provided that comprise a microvesicle derived from an edible plant. The microvesicles are coated with a plasma membrane derived from a targeting cell and can further be utilized to encapsulate a therapeutic agent. Methods for treating an inflammatory disorder and/or a cancer are further provided and include the step of administering to a subject an effective amount of a composition that includes a microvesicle coated with a plasma membrane derived from a targeting cell.

Abstract: The present invention relates to a molecule delivery technology and a carrier technology, which may selectively deliver a material to a desired specific cell and living tissue. The present invention may be utilized in the field of a drug carrier which effectively delivers an imaging probe and a therapeutic agent to an affected part.

Abstract: A method for manufacturing supported lipid bilayer on a porous silica nanoparticle with a ?-potential comprised between ?10 mV and +10 mV, the method comprising the steps of (a) providing a negatively charged supported lipid bilayer on a porous silica nanoparticle, wherein the negatively charged supported lipid bilayer has a ?-potential inferior to ?15 mV and wherein the negatively charged supported lipid bilayer comprised at least one phospholipid and; (b) adding a formulation of lipids, the lipids being 1,2-dioleoyl-3-trimethylammonium-propane alias DOTAP, cholesterol and at least one lipid different from DOTAP and cholesterol. The method further comprises the step of (c) performing an ultra-sonication for promoting DOTAP incorporation. The method can be supplemented by the step of addition of alginate and the step of cross-linking the alginate. Also a nanocapsule and composition comprising the nanocapsule.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).

Abstract: Methods of producing a transdermal delivery patches are described comprising the preparation of a uniform suspension of drug particles. A plasticizer is added to the suspension. A solution of an adhesive is add to the suspension to form a drug suspension in the adhesive mixture. The drug suspension is coated on a release liner and all solvents are evaporated to form a solid drug reservoir layer. A medical device for transdermal administration of a drug can include the solid drug reservoir layer. Suitable drugs include fentanyl and sufentanil.

Abstract: Apparatuses, methods, and compositions for administering vaporized caryophyllene compositions to a human subject in need thereof. The caryophyllene compositions can be administered via a handheld electronic device that vaporizes pure, essentially pure, or substantially pure caryophyllene (beta caryophyllene and/or alpha caryophyllene) in small doses for inhalation by a user. Some compositions do not include or contain additional constituents, carriers, or additives, and demonstrate beneficial physiological effects that are not seen when alpha caryophyllene or beta caryophyllene is administered orally or by injection.

Abstract: The invention provides novel iso-osmotic or near iso-osmotic formulations of fluorocarbon emulsions that are useful as oxygen therapeutics, for example, for treating sickle cell disease and related diseases and conditions, as well as methods of preparation and use thereof.